236 related articles for article (PubMed ID: 29644723)
21. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
22. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
23. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.
Abadeh A; Shehadeh S; Betschel S; Waserman S; Cameron DW; Cowan J
PLoS One; 2023; 18(11):e0294408. PubMed ID: 37971974
[TBL] [Abstract][Full Text] [Related]
25. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
Bauhofer A; Dietrich RL; Schmeidl R
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
[TBL] [Abstract][Full Text] [Related]
26. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus.
Jolles S; Michallet M; Agostini C; Albert MH; Edgar D; Ria R; Trentin L; Lévy V
Eur J Haematol; 2021 Apr; 106(4):439-449. PubMed ID: 33453130
[TBL] [Abstract][Full Text] [Related]
27. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
[TBL] [Abstract][Full Text] [Related]
28. Autologous stem cell transplantation in hematological malignancies.
Gorin NC
Springer Semin Immunopathol; 2004 Nov; 26(1-2):3-30. PubMed ID: 15480668
[No Abstract] [Full Text] [Related]
29. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
30. Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.
Soshnick SH; Joseph T; Bennett NJ
J Clin Immunol; 2021 Aug; 41(6):1208-1212. PubMed ID: 33740168
[TBL] [Abstract][Full Text] [Related]
31. Rituximab and immune deficiency: case series and review of the literature.
Kaplan B; Kopyltsova Y; Khokhar A; Lam F; Bonagura V
J Allergy Clin Immunol Pract; 2014; 2(5):594-600. PubMed ID: 25213054
[TBL] [Abstract][Full Text] [Related]
32. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
[TBL] [Abstract][Full Text] [Related]
33. Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?
Noto A; Cassin R; Mattiello V; Bortolotti M; Reda G; Barcellini W
Front Immunol; 2023; 14():1062376. PubMed ID: 37122737
[TBL] [Abstract][Full Text] [Related]
34. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
35. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
36. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
38. Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors.
Ke X; Yang Y; Zhao X; Wang L
Chin Med J (Engl); 2001 Feb; 114(2):196-9. PubMed ID: 11780206
[TBL] [Abstract][Full Text] [Related]
39. Secondary immunodeficiency in lymphoproliferative malignancies.
Friman V; Winqvist O; Blimark C; Langerbeins P; Chapel H; Dhalla F
Hematol Oncol; 2016 Sep; 34(3):121-32. PubMed ID: 27402426
[TBL] [Abstract][Full Text] [Related]
40. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
